• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹水肿瘤细胞对两种烷化剂的摄取差异。

Different uptake of two alkylating substances by ascites tumor cells.

作者信息

Schmidt H, Liss E

出版信息

Arzneimittelforschung. 1978;28(11):2150-2.

PMID:582920
Abstract

Considerable quantitative differences have been observed between alkylating agents with respect to their effect on cell multiplication of tumor cells. The ethyleneimine derivative triaziquone is approximately a thousand times more effective than the biologically active conversion products of the nitrogen mustard derivative cyclophosphamide. The main difference may be directly related to the extent to which each of the two substances is able to pass into the cells. After a 60-min incubation period approximately 1% of the cyclophosphamide conversion products have been bound by ascites tumor cells. The uptake of the more lipophilic triaziquone, however, is nearly 50% under identical conditions.

摘要

关于烷化剂对肿瘤细胞增殖的影响,已观察到相当大的定量差异。乙烯亚胺衍生物三嗪醌的效力约为氮芥衍生物环磷酰胺生物活性转化产物的一千倍。主要差异可能直接与这两种物质各自进入细胞的程度有关。孵育60分钟后,约1%的环磷酰胺转化产物已被腹水肿瘤细胞结合。然而,在相同条件下,亲脂性更强的三嗪醌的摄取率接近50%。

相似文献

1
Different uptake of two alkylating substances by ascites tumor cells.腹水肿瘤细胞对两种烷化剂的摄取差异。
Arzneimittelforschung. 1978;28(11):2150-2.
2
[Inhibition of desoxyribonucleic acid (DNA) synthesis and modification of cell multiplication of Yoshida ascites tumor cells by alkylating substances].[烷基化物质对吉田腹水瘤细胞脱氧核糖核酸(DNA)合成的抑制及细胞增殖的改变]
Arzneimittelforschung. 1969 Jul;19(7):1137-40.
3
Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.环磷酰胺耐药的吉田腹水瘤细胞及其对某些烷化剂的交叉耐药性。
J Cancer Res Clin Oncol. 1979 Jul 27;94(3):257-63. doi: 10.1007/BF00419285.
4
[Pharmacodynamic effect of alkylating cytostatics].[烷化剂类细胞抑制剂的药效学作用]
Dtsch Med J. 1968 Mar 5;19(5):137-41.
5
Selective inhibition of thymidine transport at low doses of the alkylating agents triethyleneiminobenzoquinone (Trenimon).低剂量烷化剂三亚乙基亚胺苯醌(Trenimon)对胸苷转运的选择性抑制作用
Exp Cell Res. 1975 Feb;90(2):357-64. doi: 10.1016/0014-4827(75)90325-0.
6
[Stimulation of DPN metabolic processes in ascites tumors by low dosage roentgen irradiation and trenimon].[低剂量X射线照射与三磷酸腺苷对腹水肿瘤中DPN代谢过程的刺激作用]
Biochem Z. 1966 Mar 28;344(2):153-66.
7
Interaction of the alkylating antitumor agent 2,3,5-tris(ethyleneimino)benzoquinone with the plasma membrane of Ehrlich ascites tumor cells.
Cancer Res. 1981 Jan;41(1):289-93.
8
Depression of histone acetylation by alkylating antitumor agents in murine cells.
Cancer Res. 1984 Aug;44(8):3336-9.
9
Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.
Cancer Treat Rep. 1976 Apr;60(4):423-7.
10
Mechanism of cyclophosphamide activation.环磷酰胺的活化机制。
Gan. 1970 Apr;61(2):145-51.

引用本文的文献

1
An exon-based comparative variant analysis pipeline to study the scale and role of frameshift and nonsense mutation in the human-chimpanzee divergence.一种基于外显子的比较变异分析流程,用于研究移码突变和无义突变在人类与黑猩猩分化过程中的规模和作用。
Comp Funct Genomics. 2009;2009:406421. doi: 10.1155/2009/406421. Epub 2009 Oct 22.
2
Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.环磷酰胺耐药的吉田腹水瘤细胞及其对某些烷化剂的交叉耐药性。
J Cancer Res Clin Oncol. 1979 Jul 27;94(3):257-63. doi: 10.1007/BF00419285.